BioWednesday Webinar: How Will Covid-19 Influence Site Selection for Future Trials?
Registration is now closed. Please email alicia@onenucleus.com to be added to the waitlist.
The pandemic has clearly led to huge disruption in clinical trials which will have significant impact on innovative drug pipelines. Undertaking multi-centre, often international studies, what criteria shape clinical trial site selection and will they differ post Covid-19?
Agenda
Opening Presentation: How the clinical trial space has been impacted by Covid-19
Mohamed Abukar, Data Analyst, GlobalData
Panel Q&A
Moderator
Dr Karen O'Hanlon, VP, Clinical Operations, Boyd Consultants Limited
Panel
Nele Langenaken, COO, Cerba Research
Dr Edward Littler, COO, ReViral Ltd
Phil Barrington, Senior Partner and Paul Branthwaite, Senior Partner & Client/BD Lead, tranScrip
Prices
One Nucleus Members: Free
Non-Members: £50 +VAT
Academics: please contact Alicia
London, SW1X 7EE
United Kingdom